PDT Partners’s Roivant Sciences ROIV Stock Holding History

PDT Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.83M	Sell	108,100 -268,409	-71%	-$7.93M	0.2%	161
2026 Q1	$10.4M	Sell	376,509 -88,435	-19%	-$2.27M	0.62%	36
2025 Q4	$10.1M	Sell	464,944 -152,518	-25%	-$3.01M	0.65%	24
2025 Q3	$9.34M	Sell	617,462 -177,964	-22%	-$2.2M	0.59%	27
2025 Q2	$8.96M	Buy	795,426 +226,535	+40%	+$2.46M	0.51%	33
2025 Q1	$5.74M	Buy	568,891 +60,460	+12%	+$654K	0.41%	48
2024 Q4	$6.01M	Buy	508,431 +109,324	+27%	+$1.29M	0.53%	17
2024 Q3	$4.61M	Buy	399,107 +215,000	+117%	+$2.45M	0.41%	36
2024 Q2	$1.95M	Buy	184,107 +111,907	+155%	+$1.23M	0.18%	207
2024 Q1	$761K	Sell	72,200 -85,494	-54%	-$922K	0.07%	384
2023 Q4	$1.77M	Buy	+157,694	New	+$1.54M	0.2%	177
2023 Q2	–	Sell	-69,769	Closed	-$515K	–	639
2023 Q1	$515K	Buy	+69,769	New	+$574K	0.07%	385

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

PDT Partners's ROIV Position: Q2 2026 in Review

PDT Partners reduced its Roivant Sciences (ROIV) stake by 71% in Q2 2026, selling an estimated $7.93M and leaving 108,100 shares worth $3.83M. The position accounts for 0.2% of the portfolio, ranked #161.

PDT Partners first reported a position in ROIV in Q1 2023 and has held it in 12 quarters since. The position peaked at $10.4M in Q1 2026. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

PDT Partners held 108,100 shares of Roivant Sciences worth $3.83M as of Q2 2026.
PDT Partners sold 268,409 Roivant Sciences shares in Q2 2026, an estimated $7.93M.
Roivant Sciences made up 0.2% of PDT Partners's portfolio in Q2 2026, its #161 holding.
PDT Partners first reported a position in Roivant Sciences in Q1 2023 and has held it in 12 quarters since.
PDT Partners's Roivant Sciences position peaked at $10.4M in Q1 2026.
500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.